BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32641413)

  • 41. Epigenetic inactivation of the canonical Wnt antagonist secreted frizzled-related protein 1 in hepatocellular carcinoma cells.
    Wu Y; Li J; Sun CY; Zhou Y; Zhao YF; Zhang SJ
    Neoplasma; 2012; 59(3):326-32. PubMed ID: 22296502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis.
    Yu J; Ni M; Xu J; Zhang H; Gao B; Gu J; Chen J; Zhang L; Wu M; Zhen S; Zhu J
    BMC Cancer; 2002 Nov; 2():29. PubMed ID: 12433278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis.
    Lee S; Lee HJ; Kim JH; Lee HS; Jang JJ; Kang GH
    Am J Pathol; 2003 Oct; 163(4):1371-8. PubMed ID: 14507645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
    Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
    Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.
    Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Lehmann U
    J Pathol; 2014 Aug; 233(4):392-401. PubMed ID: 24838394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
    Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
    J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
    Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
    Hu BS; Xiong SM; Li G; Li JP
    Tumour Biol; 2016 Oct; 37(10):13445-13453. PubMed ID: 27465549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice.
    Chappell G; Kutanzi K; Uehara T; Tryndyak V; Hong HH; Hoenerhoff M; Beland FA; Rusyn I; Pogribny IP
    Int J Cancer; 2014 Jun; 134(12):2778-88. PubMed ID: 24242335
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.
    von Felden J; Craig AJ; Garcia-Lezana T; Labgaa I; Haber PK; D'Avola D; Asgharpour A; Dieterich D; Bonaccorso A; Torres-Martin M; Sia D; Sung MW; Tabrizian P; Schwartz M; Llovet JM; Villanueva A
    Oncogene; 2021 Jan; 40(1):140-151. PubMed ID: 33097857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
    Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
    Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TERT promoter mutations in primary liver tumors.
    Nault JC; Zucman-Rossi J
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
    Xue KX
    Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
    Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
    World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma.
    Jia Y; Yang Y; Liu S; Herman JG; Lu F; Guo M
    Epigenetics; 2010; 5(8):743-9. PubMed ID: 20716954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.